

Supplementary Online Content

Zhao L, Li D, Zheng H, et al. Acupuncture as adjunctive therapy for chronic stable angina: a randomized clinical trial. *JAMA Intern Med*. Published online July 29, 2019.

doi:10.1001/jamainternmed.2019.2407


eFigure. Location of Acupoints and Nonacupoints

eTable 1. CCS Angina Grade and 6WMD During the Baseline and at the End of Therapy

eTable 2. HRV During the Baseline and at the End of Therapy

This supplementary material has been provided by the authors to give readers additional information about their work.

eFigure. Location of Acupoints and Nonacupoints



PC6: 2 *cun* above of the transverse crease of the wrist, between the tendons of m. palmaris longus and m. flexor carpi radialis.

HT5: 1 *cun* above the transverse crease of the wrist, on the palmar aspect of the forearm, on the radial border of the tendon of m. flexor carpi radialis.

LU9: on the transverse crease of the wrist, in the depression on the radial side of the radial artery.

LU6: in the forearm, 7 *cun* above the transverse crease of the wrist, on the line joining LU9 and LU5.

Sham point 1: on the ulnar side of the arm, half way between the epicondylus medialis of the humerus and the ulnar side of the wrist.

Sham point 2: on the front arm of deltoid muscle and biceps brachi junction.

eTable 1. CCS Angina Grade and 6MWD During the Baseline and at the End of Therapy

Outcome measure	DAM	NAM	SA	WL	P value
CCS angina grade in Baseline, n (%)					.2491
I	44(44.4)	52(52.5)	42(41.5)	42(42.4)	
II	54(54.5)	47(47.4)	54(53.4)	54(54.5)	
III	1(1.0)	0(0.0)	4(3.9)	3(3.0)	
IV	0(0.0)	0(0.0)	1(0.9)	0(0.0)	
CCS angina grade in 1-4 wk, n (%)					.0125
I	58(63.04)	59(62.77)	44(44.44)	47(50.00)	
II	33(35.87)	34(36.17)	51(51.52)	44(46.81)	
III	1(1.09)	0(0.00)	4(4.04)	3(3.19)	
IV	0(0.00)	1(1.06)	0(0.00)	0(0.00)	
Changes in CCS angina grade, n (%)					.036
No change or deterioration	72(78.26)	83(88.30)	90(90.91)	85(90.43)	
≥ 1 class improvement	20(21.74)	11(11.70)	9 (9.09)	9(9.57)	
6MWD, m, mean (SD)					
baseline	379.50(68.47)	394.90(82.18)	378.80(78.89)	381.0(83.61)	.424
Treatment, 1-4 wk	408.60(65.02)	415.10(82.63)	384.20(75.91)	385.0(77.80)	.006

Note:

CCS: Canadian Cardiovascular Society; 6MWD: 6-minute walk distance test

eTable 2. HRV During the Baseline and at the End of Therapy

Outcome measure	DAM (n=67)	NAM (n=66)	SA (n=66)	WL (n=59)	P Value
LF, ms², mean (SD)					
baseline	575.79(110.14)	592.88(103.70)	567.23(135.16)	607.88(119.43)	.2202
1-4 wk	513.41(98.86)	533.65(89.77)	540.71(115.92)	562.38(126.01)	.0888
HF, ms², mean (SD)					
baseline	138.20(35.40)	134.99(42.78)	136.99(46.42)	132.54(42.63)	.8839
1-4 wk	156.02(42.53)	145.09(36.07)	142.92(37.70)	146.46(41.50)	.2349
LF/HF					
baseline	4.48(1.53)	4.94(2.52)	4.85(3.07)	5.26(2.56)	.2875
1-4 wk	3.61(1.53)	5.54(13.87)	4.11(1.65)	4.22(1.91)	.0404
SDNN, ms, mean (SD)					
baseline	126.56(45.91)	137.23(59.26)	128.71(34.80)	127.43(32.09)	.4455
1-4 wk	129.40(51.00)	135.14(45.81)	140.51(107.19)	126.00(31.53)	.4750
SDANN, ms, mean (SD)					
baseline	105.87(42.72)	149.65(93.70)	121.10(44.83)	118.27(36.82)	.0756
1-4 wk	120.49(46.17)	121.01(29.46)	168.74(27.50)	118.26(35.04)	.5195
rMSDD, ms, mean (SD)					
baseline	36.86(25.69)	36.89(28.25)	43.15(30.80)	36.73(21.89)	.4805
1-4 wk	39.06(35.71)	37.27(34.25)	42.47(36.83)	40.66(31.14)	.7499

PNN50 %, mean (SD)					
baseline	8.82(10.17)	8.51(8.79)	10.39(11.03)	9.47(11.90)	.6576
1-4 wk	8.28(9.08)	8.60(8.02)	9.23(9.14)	9.56(12.92)	.4082

Note: A 24-hour recording was considered eligible for this study if it had more than 12 hours of analyzable data, had half of night-time and day-time periods analyzable, and if more than 50% of the recording revealed sinus rhythm.

LF: low frequency; HF: high frequency; SDNN: standard deviation of normal RR (NN) intervals; SDANN: standard deviation of 5-minute mean RR intervals; rMSSD: root-mean square of difference of successive RR intervals; PNN50: proportion of adjacent RR intervals more than 50 ms different.